12,924 Shares of Alnylam Pharmaceuticals, Inc. $ALNY Purchased by UNIVEST FINANCIAL Corp

UNIVEST FINANCIAL Corp bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 12,924 shares of the biopharmaceutical company’s stock, valued at approximately $3,189,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Legal & General Group Plc purchased a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $278,321,000. Bank of New York Mellon Corp purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter worth approximately $148,128,000. Canada Pension Plan Investment Board acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $100,618,000. Korea Investment CORP acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $74,553,000. Finally, Pictet Asset Management Holding SA grew its stake in shares of Alnylam Pharmaceuticals by 77.7% during the 3rd quarter. Pictet Asset Management Holding SA now owns 495,168 shares of the biopharmaceutical company’s stock worth $122,783,000 after purchasing an additional 216,555 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Bryan Supran sold 1,758 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $226.88, for a total value of $398,855.04. Following the sale, the executive vice president directly owned 12,807 shares in the company, valued at approximately $2,905,652.16. The trade was a 12.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 0.86% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on ALNY. BMO Capital Markets reiterated an “outperform” rating and issued a $290.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, October 30th. Stifel Nicolaus lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $225.00 price target on the stock. in a research report on Thursday, October 29th. HC Wainwright restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, October 28th. Royal Bank Of Canada cut their price objective on shares of Alnylam Pharmaceuticals from $345.00 to $280.00 and set an “outperform” rating for the company in a report on Friday, October 30th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Alnylam Pharmaceuticals from $375.00 to $369.00 and set an “overweight” rating for the company in a research report on Wednesday, September 30th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $305.86.

View Our Latest Report on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $159.85 on Thursday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.43 and a current ratio of 2.48. The firm has a fifty day moving average of $223.45 and a 200 day moving average of $277.97. The firm has a market cap of $21.41 billion, a PE ratio of 8.30 and a beta of 0.42. Alnylam Pharmaceuticals, Inc. has a one year low of $149.18 and a one year high of $479.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The business had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. During the same period last year, the firm posted $2.90 earnings per share. The company’s revenue was up 16.7% compared to the same quarter last year. As a group, research analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.85 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

(Free Report)

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.

Further Reading

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.